GeneDx Holdings Corp. $WGS Stock: Moody Aldrich Partners LLC Boosts Stake

Moody Aldrich Partners LLC grew its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS) by 131.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 36,064 shares of the company’s stock after purchasing an additional 20,511 shares during the quarter. Moody Aldrich Partners LLC’s holdings in GeneDx were worth $2,607,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in WGS. Fifth Third Bancorp bought a new stake in shares of GeneDx during the 1st quarter worth approximately $31,000. Nykredit A S bought a new position in shares of GeneDx in the second quarter valued at $38,000. Sterling Capital Management LLC grew its stake in shares of GeneDx by 851.4% in the third quarter. Sterling Capital Management LLC now owns 666 shares of the company’s stock valued at $48,000 after buying an additional 596 shares in the last quarter. OP Asset Management Ltd acquired a new position in GeneDx during the first quarter worth $45,000. Finally, Strs Ohio increased its holdings in GeneDx by 8.7% during the first quarter. Strs Ohio now owns 2,500 shares of the company’s stock worth $161,000 after buying an additional 200 shares during the last quarter. Institutional investors and hedge funds own 61.72% of the company’s stock.

GeneDx Stock Up 3.1%

WGS opened at $64.69 on Thursday. The stock has a fifty day moving average of $79.48 and a 200-day moving average of $72.91. The company has a market capitalization of $1.93 billion, a P/E ratio of -17.77 and a beta of 1.95. GeneDx Holdings Corp. has a fifty-two week low of $32.21 and a fifty-two week high of $170.87. The company has a debt-to-equity ratio of 0.40, a quick ratio of 3.06 and a current ratio of 3.30.

GeneDx (NASDAQ:WGS) last released its quarterly earnings results on Monday, August 3rd. The company reported $0.01 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.20. GeneDx had a negative net margin of 23.41% and a positive return on equity of 4.12%. The business had revenue of $114.44 million for the quarter, compared to the consensus estimate of $111.01 million. During the same period in the prior year, the company posted $0.36 earnings per share. On average, equities analysts expect that GeneDx Holdings Corp. will post -0.41 EPS for the current year.

Insider Activity

In other GeneDx news, CFO Kevin Feeley sold 3,728 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total value of $363,890.08. Following the completion of the sale, the chief financial officer owned 44,945 shares of the company’s stock, valued at $4,387,081.45. The trade was a 7.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Katherine Stueland sold 10,501 shares of the business’s stock in a transaction dated Wednesday, September 16th. The shares were sold at an average price of $97.61, for a total transaction of $1,025,002.61. Following the completion of the sale, the chief executive officer directly owned 115,476 shares of the company’s stock, valued at $11,271,612.36. This represents a 8.34% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 19,206 shares of company stock valued at $1,808,056 in the last quarter. Corporate insiders own 25.17% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on WGS shares. Canaccord Genuity Group upped their price target on shares of GeneDx from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Weiss Ratings raised shares of GeneDx from a “sell (e+)” rating to a “sell (d)” rating in a research report on Tuesday, August 4th. Guggenheim lifted their price objective on shares of GeneDx from $74.00 to $83.00 and gave the company a “buy” rating in a research report on Thursday, October 1st. Zacks Research lowered shares of GeneDx from a “strong-buy” rating to a “hold” rating in a research note on Friday, October 9th. Finally, Wall Street Zen raised shares of GeneDx from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Seven investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $90.86.

GeneDx Profile

GeneDx Holdings Corp., doing business as GeneDx, is a genomic diagnostics company that provides genetic testing and interpretation services for patients with suspected rare and inherited conditions. The company combines sequencing technologies with clinical expertise and data analysis to help healthcare professionals identify genetic causes of disease and support diagnosis, treatment planning and patient management.

GeneDx’s offerings include whole exome and whole genome sequencing, as well as targeted testing for specific genetic disorders and hereditary cancer conditions.